Published in Antimicrob Agents Chemother on June 01, 2000
In vivo imaging of specialized bone marrow endothelial microdomains for tumour engraftment. Nature (2005) 6.60
A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors. Proc Natl Acad Sci U S A (2003) 3.72
Inhibition of lysosome and proteasome function enhances human immunodeficiency virus type 1 infection. J Virol (2005) 2.05
Analysis of the mechanism by which the small-molecule CCR5 antagonists SCH-351125 and SCH-350581 inhibit human immunodeficiency virus type 1 entry. J Virol (2003) 1.97
The CCR5 and CXCR4 coreceptors are both used by human immunodeficiency virus type 1 primary isolates from subtype C. J Virol (2003) 1.86
AMD3100 mobilizes hematopoietic stem cells with long-term repopulating capacity in nonhuman primates. Blood (2006) 1.79
Pathogen induction of CXCR4/TLR2 cross-talk impairs host defense function. Proc Natl Acad Sci U S A (2008) 1.77
G-CSF down-regulation of CXCR4 expression identified as a mechanism for mobilization of myeloid cells. Blood (2006) 1.76
A phase 1 clinical trial of long-term, low-dose treatment of WHIM syndrome with the CXCR4 antagonist plerixafor. Blood (2014) 1.66
The CXCR4 antagonist plerixafor corrects panleukopenia in patients with WHIM syndrome. Blood (2011) 1.65
Pharmacological mobilization of endogenous stem cells significantly promotes skin regeneration after full-thickness excision: the synergistic activity of AMD3100 and tacrolimus. J Invest Dermatol (2014) 1.61
CXCR4 blockade augments bone marrow progenitor cell recruitment to the neovasculature and reduces mortality after myocardial infarction. Proc Natl Acad Sci U S A (2010) 1.61
Sialoadhesin expressed on IFN-induced monocytes binds HIV-1 and enhances infectivity. PLoS One (2008) 1.59
Phenotypic and immunologic comparison of clade B transmitted/founder and chronic HIV-1 envelope glycoproteins. J Virol (2011) 1.55
AMD3100, a CxCR4 antagonist, attenuates allergic lung inflammation and airway hyperreactivity. Am J Pathol (2002) 1.54
CXC-chemokine receptor 4 antagonist AMD3100 promotes cardiac functional recovery after ischemia/reperfusion injury via endothelial nitric oxide synthase-dependent mechanism. Circulation (2012) 1.53
Human term placenta as a source of hematopoietic cells. Exp Biol Med (Maywood) (2009) 1.51
Engineering HIV-resistant human CD4+ T cells with CXCR4-specific zinc-finger nucleases. PLoS Pathog (2011) 1.50
HIV-1 replication in the central nervous system occurs in two distinct cell types. PLoS Pathog (2011) 1.45
Mobilization of endogenous stem cell populations enhances fracture healing in a murine femoral fracture model. Cytotherapy (2013) 1.44
Mobilization of hematopoietic stem and progenitor cells using inhibitors of CXCR4 and VLA-4. Leukemia (2011) 1.44
Emerging targets in cancer management: role of the CXCL12/CXCR4 axis. Onco Targets Ther (2013) 1.44
CXCL12-CXCR4 signalling axis confers gemcitabine resistance to pancreatic cancer cells: a novel target for therapy. Br J Cancer (2010) 1.43
Therapeutic antibodies directed at G protein-coupled receptors. MAbs (2010) 1.41
HIV-1 entry inhibitors: an overview. Curr Opin HIV AIDS (2009) 1.41
Feline immunodeficiency virus targets activated CD4+ T cells by using CD134 as a binding receptor. Proc Natl Acad Sci U S A (2004) 1.38
Molecular imaging of CXCR4 receptor expression in human cancer xenografts with [64Cu]AMD3100 positron emission tomography. Cancer Res (2010) 1.32
Small molecule inhibitors of CXCR4. Theranostics (2013) 1.30
Mobilization as a preparative regimen for hematopoietic stem cell transplantation. Blood (2006) 1.28
Characterization of a thymus-tropic HIV-1 isolate from a rapid progressor: role of the envelope. Virology (2004) 1.26
EphB2 and EphB4 receptors forward signaling promotes SDF-1-induced endothelial cell chemotaxis and branching remodeling. Blood (2006) 1.23
Structural conservation predominates over sequence variability in the crown of HIV type 1's V3 loop. AIDS Res Hum Retroviruses (2010) 1.21
Transcription factor Gfi-1 induced by G-CSF is a negative regulator of CXCR4 in myeloid cells. Blood (2007) 1.16
64Cu-AMD3100--a novel imaging agent for targeting chemokine receptor CXCR4. Bioorg Med Chem (2009) 1.16
Selective enhancement of donor hematopoietic cell engraftment by the CXCR4 antagonist AMD3100 in a mouse transplantation model. PLoS One (2010) 1.12
HIV-1 entry inhibitors: recent development and clinical use. Curr Opin Virol (2013) 1.07
Combination of drug therapy in acute lymphoblastic leukemia with a CXCR4 antagonist. Leukemia (2011) 1.06
The increase in surface CXCR4 expression on lung extravascular neutrophils and its effects on neutrophils during endotoxin-induced lung injury. Cell Mol Immunol (2011) 1.05
CXCR4 signaling mediates morphine-induced tactile hyperalgesia. Brain Behav Immun (2010) 1.05
Evolution of the HIV-1 env gene in the Rag2-/- gammaC-/- humanized mouse model. J Virol (2009) 1.05
The intricate role of CXCR4 in cancer. Adv Cancer Res (2014) 1.04
Selective targeting of ITK blocks multiple steps of HIV replication. Proc Natl Acad Sci U S A (2008) 1.04
Chemokine signaling in cancer: one hump or two? Semin Cancer Biol (2008) 1.04
Persistent CXCR4 expression after preoperative chemoradiotherapy predicts early recurrence and poor prognosis in esophageal cancer. World J Gastroenterol (2006) 1.03
Challenges for heart disease stem cell therapy. Vasc Health Risk Manag (2012) 1.02
A duodenally absorbable CXC chemokine receptor 4 antagonist, KRH-1636, exhibits a potent and selective anti-HIV-1 activity. Proc Natl Acad Sci U S A (2003) 1.00
Noninvasive imaging reveals inhibition of ovarian cancer by targeting CXCL12-CXCR4. Neoplasia (2011) 1.00
Multiple-dose escalation study of the safety, pharmacokinetics, and biologic activity of oral AMD070, a selective CXCR4 receptor inhibitor, in human subjects. Antimicrob Agents Chemother (2007) 1.00
Attenuation of osteoarthritis via blockade of the SDF-1/CXCR4 signaling pathway. Arthritis Res Ther (2012) 0.97
Association of progressive CD4(+) T cell decline in SIV infection with the induction of autoreactive antibodies. PLoS Pathog (2009) 0.96
Discovery of small-molecule human immunodeficiency virus type 1 entry inhibitors that target the gp120-binding domain of CD4. J Virol (2005) 0.96
Antagonism of stromal cell-derived factor-1alpha reduces infarct size and improves ventricular function after myocardial infarction. Pflugers Arch (2007) 0.96
CXCR4 inhibitors selectively eliminate CXCR4-expressing human acute myeloid leukemia cells in NOG mouse model. Cell Death Dis (2012) 0.94
Inhibition of Porphyromonas gingivalis-induced periodontal bone loss by CXCR4 antagonist treatment. Mol Oral Microbiol (2012) 0.92
The novel CXCR4 antagonist KRH-3955 is an orally bioavailable and extremely potent inhibitor of human immunodeficiency virus type 1 infection: comparative studies with AMD3100. Antimicrob Agents Chemother (2009) 0.92
Proteoglycan 4, a novel immunomodulatory factor, regulates parathyroid hormone actions on hematopoietic cells. Am J Pathol (2011) 0.91
Discovery of very late antigen-4 (VLA-4, alpha4beta1 integrin) allosteric antagonists. J Biol Chem (2010) 0.91
In vitro characterization of multidrug-resistant HIV-1 isolates from a recently infected patient associated with dual tropism and rapid disease progression. J Acquir Immune Defic Syndr (2008) 0.90
Chemokines and chemokine receptors: update on utility and challenges for the clinician. Surgery (2014) 0.89
AMD3100 disrupts the cross-talk between chronic lymphocytic leukemia cells and a mesenchymal stromal or nurse-like cell-based microenvironment: pre-clinical evidence for its association with chronic lymphocytic leukemia treatments. Haematologica (2011) 0.88
Adaptation of the human immunodeficiency virus type 1 envelope glycoproteins to new world monkey receptors. J Virol (2007) 0.86
Antileukemia activity of the novel peptidic CXCR4 antagonist LY2510924 as monotherapy and in combination with chemotherapy. Blood (2015) 0.86
Effects of plerixafor in combination with BCR-ABL kinase inhibition in a murine model of CML. Blood (2012) 0.86
CXCR4 Expression and Treatment with SDF-1α or Plerixafor Modulate Proliferation and Chemosensitivity of Colon Cancer Cells. Transl Oncol (2013) 0.85
The root extract of the medicinal plant Pelargonium sidoides is a potent HIV-1 attachment inhibitor. PLoS One (2014) 0.85
CXCR4 and a cell-extrinsic mechanism control immature B lymphocyte egress from bone marrow. J Exp Med (2014) 0.85
CXCR4 in Cancer and Its Regulation by PPARgamma. PPAR Res (2008) 0.85
Physiology and pharmacology of plerixafor. Transfus Med Hemother (2013) 0.85
Initial assessment of the role of CXC chemokine receptor 4 after polytrauma. Mol Med (2012) 0.84
Chemokine (C-X-C motif) receptor 4 and atypical chemokine receptor 3 regulate vascular α₁-adrenergic receptor function. Mol Med (2014) 0.84
IL-1α and complement cooperate in triggering local neutrophilic inflammation in response to adenovirus and eliminating virus-containing cells. PLoS Pathog (2014) 0.84
Role of Chemokines and Chemokine Receptors in Prostate Cancer Development and Progression. J Cancer Sci Ther (2010) 0.83
Attenuation of cartilage pathogenesis in post-traumatic osteoarthritis (PTOA) in mice by blocking the stromal derived factor 1 receptor (CXCR4) with the specific inhibitor, AMD3100. J Orthop Res (2015) 0.83
Inhibition of human immunodeficiency virus replication by a dual CCR5/CXCR4 antagonist. J Virol (2004) 0.83
Adult mouse subventricular zones stimulate glioblastoma stem cells specific invasion through CXCL12/CXCR4 signaling. Neuro Oncol (2014) 0.83
Ligand-guided optimization of CXCR4 homology models for virtual screening using a multiple chemotype approach. J Comput Aided Mol Des (2010) 0.83
Progenitors mobilized by gamma-tocotrienol as an effective radiation countermeasure. PLoS One (2014) 0.82
RT-SHIV, an infectious CCR5-tropic chimeric virus suitable for evaluating HIV reverse transcriptase inhibitors in macaque models. AIDS Res Ther (2009) 0.81
Identification of ghrelin receptor blocker, D-[Lys3] GHRP-6 as a CXCR4 receptor antagonist. Int J Biol Sci (2011) 0.80
CXCR4: a virus's best friend? Infect Genet Evol (2014) 0.80
A Novel Role of Proline Oxidase in HIV-1 Envelope Glycoprotein-induced Neuronal Autophagy. J Biol Chem (2015) 0.79
Plerixafor for autologous CD34 cell mobilization. Core Evid (2011) 0.79
Enhancement of the CXCL12/CXCR4 axis due to acquisition of gemcitabine resistance in pancreatic cancer: effect of CXCR4 antagonists. BMC Cancer (2016) 0.78
CXCR4-dependent infection of CD8+, but not CD4+, lymphocytes by a primary human immunodeficiency virus type 1 isolate. J Virol (2004) 0.78
Effect of low-dose ritonavir on the pharmacokinetics of the CXCR4 antagonist AMD070 in healthy volunteers. Antimicrob Agents Chemother (2008) 0.78
AMD3100/CXCR4 Inhibitor. Front Immunol (2015) 0.78
Impact of a CXCL12/CXCR4 Antagonist in Bleomycin (BLM) Induced Pulmonary Fibrosis and Carbon Tetrachloride (CCl4) Induced Hepatic Fibrosis in Mice. PLoS One (2016) 0.77
Synthesis of pyridine derivatives as potential antagonists of chemokine receptor type 4. Heterocycl Comm (2014) 0.77
Long-term follow up of patients proceeding to transplant using plerixafor mobilized stem cells and incidence of secondary myelodysplastic syndrome/AML. Bone Marrow Transplant (2013) 0.77
Blockade of hypoxia-induced CXCR4 with AMD3100 inhibits production of OA-associated catabolic mediators IL-1β and MMP-13. Mol Med Rep (2016) 0.77
Fusion Stage of HIV-1 Entry Depends on Virus-Induced Cell Surface Exposure of Phosphatidylserine. Cell Host Microbe (2017) 0.76
G protein-coupled receptors as oncogenic signals in glioma: emerging therapeutic avenues. Neuroscience (2014) 0.76
CXC chemokine receptor 4 expression, CXC chemokine receptor 4 activation, and wild-type nucleophosmin are independently associated with unfavorable prognosis in patients with acute myeloid leukemia. Clin Lymphoma Myeloma Leuk (2013) 0.76
Intravenous Administration of Endothelial Colony-Forming Cells Overexpressing Integrin β1 Augments Angiogenesis in Ischemic Legs. Stem Cells Transl Med (2015) 0.76
A Conserved Glycan in the C2 Domain of HIV-1 Envelope Acts as a Molecular Switch to Control X4 Utilization by Clonal Variants with Identical V3 Loops. PLoS One (2015) 0.76
Pretransplant mobilization with granulocyte colony-stimulating factor improves B-cell reconstitution by lentiviral vector gene therapy in SCID-X1 mice. Hum Gene Ther (2014) 0.76
Increased mobilization and yield of stem cells using plerixafor in combination with granulocyte-colony stimulating factor for the treatment of non-Hodgkin's lymphoma and multiple myeloma. Stem Cells Cloning (2011) 0.76
Supportive care in patients with acute leukaemia: historical perspectives. Blood Transfus (2014) 0.76
Identification of a major co-receptor for primary isolates of HIV-1. Nature (1996) 23.81
HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature (1996) 20.59
CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science (1996) 18.53
Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. Science (1995) 17.42
Chemokines and leukocyte traffic. Nature (1998) 9.79
Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4. Science (1999) 8.43
A highly efficacious lymphocyte chemoattractant, stromal cell-derived factor 1 (SDF-1) J Exp Med (1996) 7.97
The chemokine SDF-1 is a chemoattractant for human CD34+ hematopoietic progenitor cells and provides a new mechanism to explain the mobilization of CD34+ progenitors to peripheral blood. J Exp Med (1997) 6.39
Distinct replicative and cytopathic characteristics of human immunodeficiency virus isolates. J Virol (1988) 4.96
AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor. Nat Med (1998) 4.77
Primary, syncytium-inducing human immunodeficiency virus type 1 isolates are dual-tropic and most can use either Lestr or CCR5 as coreceptors for virus entry. J Virol (1996) 4.43
Inhibition of T-tropic HIV strains by selective antagonization of the chemokine receptor CXCR4. J Exp Med (1997) 3.62
Expression and function of CCR5 and CXCR4 on human Langerhans cells and macrophages: implications for HIV primary infection. Nat Med (1997) 3.55
Human immunodeficiency virus type 1 variants with increased replicative capacity develop during the asymptomatic stage before disease progression. J Virol (1994) 3.01
In vivo compartmentalization of human immunodeficiency virus: evidence from the examination of pol sequences from autopsy tissues. J Virol (1997) 2.71
CD4-independent association between HIV-1 gp120 and CXCR4: functional chemokine receptors are expressed in human neurons. Curr Biol (1997) 2.35
Highly potent and selective inhibition of human immunodeficiency virus by the bicyclam derivative JM3100. Antimicrob Agents Chemother (1994) 2.26
Neuronal apoptosis induced by HIV-1 gp120 and the chemokine SDF-1 alpha is mediated by the chemokine receptor CXCR4. Curr Biol (1998) 2.21
Chemokine receptors in human endothelial cells. Functional expression of CXCR4 and its transcriptional regulation by inflammatory cytokines. J Biol Chem (1998) 2.02
CXCR-4 (Fusin), a co-receptor for the type 1 human immunodeficiency virus (HIV-1), is expressed in the human brain in a variety of cell types, including microglia and neurons. Am J Pathol (1997) 2.00
Bicyclams, a class of potent anti-HIV agents, are targeted at the HIV coreceptor fusin/CXCR-4. Antiviral Res (1997) 1.90
Toward improved anti-HIV chemotherapy: therapeutic strategies for intervention with HIV infections. J Med Chem (1995) 1.85
Determinants for sensitivity of human immunodeficiency virus coreceptor CXCR4 to the bicyclam AMD3100. J Virol (1998) 1.81
Analysis of the temporal relationship between human immunodeficiency virus type 1 quasispecies in sequential blood samples and various organs obtained at autopsy. J Virol (1998) 1.52
Antiviral efficacy in vivo of the anti-human immunodeficiency virus bicyclam SDZ SID 791 (JM 3100), an inhibitor of infectious cell entry. Antimicrob Agents Chemother (1996) 1.51
V3 recombinants indicate a central role for CCR5 as a coreceptor in tissue infection by human immunodeficiency virus type 1. J Virol (1999) 1.49
Chemokines and chemokine receptors: biology and clinical relevance in inflammation and AIDS. Annu Rev Med (1999) 1.46
Chemokine receptor CXCR4 expression in endothelium. Biochem Biophys Res Commun (1998) 1.29
Activity of different bicyclam derivatives against human immunodeficiency virus depends on their interaction with the CXCR4 chemokine receptor. Mol Pharmacol (1999) 1.26
The human immunodeficiency virus (HIV)-type 1 coreceptor CXCR-4 (fusin) is preferentially expressed on the more immature CD34+ hematopoietic stem cells. Ann Hematol (1998) 0.90
Evaluation of the potential of ion pair formation to improve the oral absorption of two potent antiviral compounds, AMD3100 and PMPA. Int J Pharm (1999) 0.88
Chemokine receptor antagonists: novel therapeutics for inflammation and AIDS. Expert Opin Investig Drugs (1998) 0.82
Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med (1999) 12.68
Neonatal tolerance revisited: turning on newborn T cells with dendritic cells. Science (1996) 5.31
Long-term culture and fine specificity of human cytotoxic T-lymphocyte clones reactive with human immunodeficiency virus type 1. Proc Natl Acad Sci U S A (1989) 4.45
HIV-1 reverse transcriptase is a target for cytotoxic T lymphocytes in infected individuals. Science (1988) 3.12
Vaccinia virus expression vectors. Annu Rev Immunol (1987) 2.75
Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide. Biol Blood Marrow Transplant (2002) 2.69
Regulation of death receptor expression and TRAIL/Apo2L-induced apoptosis by NF-kappaB. Nat Cell Biol (2001) 1.83
Drug interactions in patients infected with human immunodeficiency virus. Clin Infect Dis (1996) 1.82
AMD3100, a potent and specific antagonist of the stromal cell-derived factor-1 chemokine receptor CXCR4, inhibits autoimmune joint inflammation in IFN-gamma receptor-deficient mice. J Immunol (2001) 1.77
Balancing justice and autonomy in clinical research with healthy volunteers. Clin Pharmacol Ther (2007) 1.68
AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data. Bone Marrow Transplant (2007) 1.65
Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy. J Clin Oncol (2001) 1.55
p53-mediated repression of nuclear factor-kappaB RelA via the transcriptional integrator p300. Cancer Res (1998) 1.51
Reduced intensity HLA-haploidentical BMT with post transplantation cyclophosphamide in nonmalignant hematologic diseases. Bone Marrow Transplant (2008) 1.45
Selective radiosensitization of p53-deficient cells by caffeine-mediated activation of p34cdc2 kinase. Nat Med (1996) 1.35
The effect of systemically administered recombinant human nerve growth factor in healthy human subjects. Ann Neurol (1994) 1.29
An epitope in human immunodeficiency virus 1 reverse transcriptase recognized by both mouse and human cytotoxic T lymphocytes. Proc Natl Acad Sci U S A (1990) 1.28
Activity of different bicyclam derivatives against human immunodeficiency virus depends on their interaction with the CXCR4 chemokine receptor. Mol Pharmacol (1999) 1.26
Effect of indomethacin and aspirin on gastric blood flow and acid secretion. J Pharmacol Exp Ther (1977) 1.25
A pharmacokinetic-pharmacodynamic model for the mobilization of CD34+ hematopoietic progenitor cells by AMD3100. Clin Pharmacol Ther (2005) 1.24
Safety and pharmacokinetics of escalating daily doses of the antituberculosis drug rifapentine in healthy volunteers. Clin Pharmacol Ther (2012) 1.23
Mutation of Asp(171) and Asp(262) of the chemokine receptor CXCR4 impairs its coreceptor function for human immunodeficiency virus-1 entry and abrogates the antagonistic activity of AMD3100. Mol Pharmacol (2001) 1.22
Mutations of the human immunodeficiency virus type 1 p6Gag domain result in reduced retention of Pol proteins during virus assembly. J Virol (1998) 1.20
Quantitative imaging and sigmoidoscopy to assess distribution of rectal microbicide surrogates. Clin Pharmacol Ther (2007) 1.19
Safety and preliminary efficacy of plerixafor (Mozobil) in combination with chemotherapy and G-CSF: an open-label, multicenter, exploratory trial in patients with multiple myeloma and non-Hodgkin's lymphoma undergoing stem cell mobilization. Bone Marrow Transplant (2009) 1.18
Oral antibiotic treatment of right-sided staphylococcal endocarditis in injection drug users: prospective randomized comparison with parenteral therapy. Am J Med (1996) 1.18
Anchor sequence-dependent endogenous processing of human immunodeficiency virus 1 envelope glycoprotein gp160 for CD4+ T cell recognition. J Exp Med (1990) 1.17
Shift of clinical human immunodeficiency virus type 1 isolates from X4 to R5 and prevention of emergence of the syncytium-inducing phenotype by blockade of CXCR4. J Virol (1999) 1.16
CD95 (Fas)-induced caspase-mediated proteolysis of NF-kappaB. Cancer Res (1998) 1.15
Dextran sulfate is poorly absorbed after oral administration. Ann Intern Med (1989) 1.13
Effect of ritonavir/saquinavir on stereoselective pharmacokinetics of methadone: results of AIDS Clinical Trials Group (ACTG) 401. J Acquir Immune Defic Syndr (2001) 1.08
Prostaglandin and histamine involvement in the gastric vasodilator action of pentagastrin. J Pharmacol Exp Ther (1977) 1.07
Pollen load size, reproductive success, and progeny kinship of naturally pollinated flowers of the tropical dry forest tree Pachira quinata (Bombacaceae). Am J Bot (2001) 1.07
Suppression of preadipocyte differentiation and promotion of adipocyte death by HIV protease inhibitors. J Biol Chem (2000) 1.06
The bicyclams, a new class of potent human immunodeficiency virus inhibitors, block viral entry after binding. Antiviral Res (1996) 1.06
Clearance of recombinant vaccinia virus expressing IL-2: role of local host immune responses. Cell Immunol (1993) 0.97
The effects of rifampin and rifabutin on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive. Clin Pharmacol Ther (1999) 0.97
Pharmacokinetic parameters of protease inhibitors and the Cmin/IC50 ratio: call for consensus. J Acquir Immune Defic Syndr (2001) 0.96
The CXCR4 antagonist AMD3100 efficiently inhibits cell-surface-expressed human immunodeficiency virus type 1 envelope-induced apoptosis. Antimicrob Agents Chemother (2000) 0.95
A randomized trial of the activity and safety of Ro 24-7429 (Tat antagonist) versus nucleoside for human immunodeficiency virus infection. The AIDS Clinical Trials Group 213 Team. J Infect Dis (1995) 0.94
Rhesus monkey macrophages infected with simian immunodeficiency virus cause rapid lysis of CD4-bearing lymphocytes. J Gen Virol (1991) 0.92
Hematopoietic SCT from partially HLA-mismatched (HLA-haploidentical) related donors. Bone Marrow Transplant (2008) 0.92
Salvage transplantation for allograft failure using fludarabine and alemtuzumab as conditioning regimen. Bone Marrow Transplant (2008) 0.92
Synthesis and structure-activity relationships of phenylenebis(methylene)-linked bis-azamacrocycles that inhibit HIV-1 and HIV-2 replication by antagonism of the chemokine receptor CXCR4. J Med Chem (1999) 0.91
Effects of mixed hematopoietic chimerism in a mouse model of bone marrow transplantation for sickle cell anemia. Blood (2001) 0.91
Antiviral activity of the bicyclam derivative JM3100 against drug-resistant strains of human immunodeficiency virus type 1. Antiviral Res (1996) 0.91
Immunologic recovery following autologous stem-cell transplantation with pre- and posttransplantation rituximab for low-grade or mantle cell lymphoma. Ann Oncol (2009) 0.90
Payment to healthy volunteers in clinical research: the research subject's perspective. Clin Pharmacol Ther (2010) 0.90
HIV cure: knocking on the door. Clin Pharmacol Ther (2013) 0.88
Clinical manifestations of acute infection with human immunodeficiency virus in a cohort of gay men. AIDS (1987) 0.88
High-dose pentoxifylline in patients with AIDS: inhibition of tumor necrosis factor production. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. J Infect Dis (1995) 0.88
Evaluation of the potential of ion pair formation to improve the oral absorption of two potent antiviral compounds, AMD3100 and PMPA. Int J Pharm (1999) 0.88
Differential effects of tipranavir plus ritonavir on atorvastatin or rosuvastatin pharmacokinetics in healthy volunteers. Antimicrob Agents Chemother (2009) 0.87
Quantitative structural activity relationship study of bis-tetraazacyclic compounds. A novel series of HIV-1 and HIV-2 inhibitors. J Med Chem (1995) 0.86
Vaccinia virus expression vectors. Ann N Y Acad Sci (1989) 0.85
Phase I/II study of the toxicity, pharmacokinetics, and activity of the HIV protease inhibitor SC-52151. J Acquir Immune Defic Syndr Hum Retrovirol (1997) 0.85
HIV genotype and phenotype--arresting resistance? JAMA (2000) 0.83
Tumor imaging with technetium-99m-labeled hydrazinonicotinamide-Fab' conjugates. J Nucl Med (1997) 0.83
Comparison of human immunodeficiency virus type 1 Pr55(Gag) and Pr160(Gag-pol) processing intermediates that accumulate in primary and transformed cells treated with peptidic and nonpeptidic protease inhibitors. Antimicrob Agents Chemother (2000) 0.83
Non-Hodgkin's lymphoma in patients with advanced HIV infection treated with zidovudine. JAMA (1991) 0.82
Effect of dipyridamole on zidovudine pharmacokinetics and short-term tolerance in asymptomatic human immunodeficiency virus-infected subjects. Antimicrob Agents Chemother (1994) 0.82
Post-transplantation cyclophosphamide for GVHD prophylaxis in severe aplastic anemia. Bone Marrow Transplant (2010) 0.81
Successful pregnancy and childbirth after reduced-intensity conditioning and partially HLA-mismatched BMT. Bone Marrow Transplant (2009) 0.80
Pharmacoecology: a new name for an old science. Clin Pharmacol Ther (2008) 0.80
Post-exposure prophylaxis revisited: new CDC guidelines. Centers for Disease Control and Prevention. Hopkins HIV Rep (1998) 0.80
X4 HIV-1 induces neuroblastoma cell death by interference with CXCL12/CXCR4 interaction. Cell Mol Biol (Noisy-le-grand) (2003) 0.79
Response: immunological tolerance. Science (1996) 0.78
Accelerator mass spectrometry measurement of intracellular concentrations of active drug metabolites in human target cells in vivo. Clin Pharmacol Ther (2010) 0.78
Diagnosis of human immunodeficiency virus infection using citrated whole blood. Clin Diagn Lab Immunol (1997) 0.78
Combination antiretroviral therapy for HIV infection. Am Fam Physician (1998) 0.78
Successful transplantation of kidney allografts in sensitized rats after syngeneic hematopoietic stem cell transplantation and fludarabine. Am J Transplant (2014) 0.78
Pharmacokinetics of antiviral polyoxometalates in rats. Antimicrob Agents Chemother (1994) 0.78
Herbal remedies in resource-poor settings: friend or foe? Clin Pharmacol Ther (2008) 0.78
A comparison of cleavable and noncleavable hydrazinopyridine linkers for the 99mTc labeling of Fab' monoclonal antibody fragments. Bioconjug Chem (1997) 0.77
Roles of vaccinia virus in the development of new vaccines. Vaccine (1988) 0.76
Safety, tolerability, and antiretroviral effects of ritonavir-nelfinavir combination therapy administered for 48 weeks. J Acquir Immune Defic Syndr (2000) 0.76
Extra-hepatic GSH-dependent metabolism of 1,2-dibromoethane (DBE) and 1,2-dibromo-3-chloropropane (DBCP) in the rat and mouse. Drug Chem Toxicol (1984) 0.75
Assessment of the potential pharmacokinetic interaction between digoxin and ethmozine. J Clin Pharmacol (1985) 0.75
Stability of colistimethate sodium in aqueous solution. Antimicrob Agents Chemother (2012) 0.75
Internal medicine: cyclosporine-a powerful new immunosuppressant. West J Med (1985) 0.75
Comparison of the effects of 3'-azidothymidine with those of neutralizing antibodies on simian immunodeficiency virus infection in macrophages. Antimicrob Agents Chemother (1993) 0.75
Pharmacokinetics and bioavailability of digitoxin by a specific assay. Eur J Clin Pharmacol (1984) 0.75
Pharmacology and drug interactions: compartmentalizing antiretrovirals. Hopkins HIV Rep (2000) 0.75
Kinetics of digitoxin and the bis- and monodigitoxosides of digitoxigenin in renal insufficiency. Clin Pharmacol Ther (1984) 0.75
Drug transporter, drug concentrations, and drug interactions. Hopkins HIV Rep (2001) 0.75
Kinetics of digitoxin and the bis- and monodigitoxosides of digitoxigenin in normal subjects. Clin Pharmacol Ther (1984) 0.75
Inactivation of human immunodeficiency virus type 1 reverse transcriptase by oltipraz: evidence for the formation of a stable adduct. Arch Biochem Biophys (1995) 0.75
The future of HIV treatment: I left my HAART in the 20th century. Hopkins HIV Rep (2001) 0.75
Bioavailability of the bis- and monodigitoxosides of digitoxigenin. Eur J Clin Pharmacol (1985) 0.75
Fat city: understanding HIV lipodystrophy. Hopkins HIV Rep (1998) 0.75